EPS for Galmed Pharmaceuticals Ltd. (GLMD) Expected At $-0.21; Broderick Brian C Decreased By $461,906 Its Canadian Natl Railway (CNI) Holding

April 19, 2018 - By reb123z

Canadian National Railway Company (NYSE:CNI) Logo

Analysts expect Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to report $-0.21 EPS on May, 21.They anticipate $0.05 EPS change or 19.23% from last quarter’s $-0.26 EPS. After having $-0.27 EPS previously, Galmed Pharmaceuticals Ltd.’s analysts see -22.22% EPS growth. The stock increased 0.64% or $0.04 during the last trading session, reaching $6.27. About 18,885 shares traded. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 11.79% since April 19, 2017 and is uptrending. It has outperformed by 0.24% the S&P500.

Broderick Brian C decreased Canadian Natl Railway (CNI) stake by 5.07% reported in 2017Q4 SEC filing. Broderick Brian C sold 5,633 shares as Canadian Natl Railway (CNI)’s stock declined 12.30%. The Broderick Brian C holds 105,378 shares with $8.69 million value, down from 111,011 last quarter. Canadian Natl Railway now has $54.26B valuation. The stock increased 0.03% or $0.02 during the last trading session, reaching $76.21. About 1.11M shares traded. Canadian National Railway Company (NYSE:CNI) has declined 1.34% since April 19, 2017 and is downtrending. It has underperformed by 12.89% the S&P500.

Among 27 analysts covering Canadian National Railway (NYSE:CNI), 11 have Buy rating, 3 Sell and 13 Hold. Therefore 41% are positive. Canadian National Railway had 72 analyst reports since July 21, 2015 according to SRatingsIntel. Cowen & Co maintained Canadian National Railway Company (NYSE:CNI) rating on Wednesday, February 28. Cowen & Co has “Buy” rating and $86.0 target. The stock of Canadian National Railway Company (NYSE:CNI) has “Underperform” rating given on Tuesday, March 6 by Bank of America. The firm earned “Hold” rating on Tuesday, October 13 by Canaccord Genuity. The firm earned “Outperform” rating on Wednesday, October 26 by Cowen & Co. The firm earned “Buy” rating on Tuesday, August 11 by Raymond James. On Wednesday, April 6 the stock rating was maintained by Citigroup with “Neutral”. The stock has “Buy” rating by Desjardins Securities on Wednesday, October 28. Bank of America upgraded Canadian National Railway Company (NYSE:CNI) on Thursday, January 12 to “Neutral” rating. The stock of Canadian National Railway Company (NYSE:CNI) has “Buy” rating given on Monday, July 17 by Cowen & Co. As per Wednesday, January 27, the company rating was upgraded by First Analysis.

Broderick Brian C increased Aqr Multi Strgy Alternative Cl stake by 34,852 shares to 458,736 valued at $4.15M in 2017Q4. It also upped Spdr Russell 3000 Etf (THRK) stake by 37,925 shares and now owns 46,725 shares. Fortive Corp was raised too.

Analysts await Canadian National Railway Company (NYSE:CNI) to report earnings on April, 23 after the close. They expect $0.80 earnings per share, down 9.09% or $0.08 from last year’s $0.88 per share. CNI’s profit will be $569.61M for 23.82 P/E if the $0.80 EPS becomes a reality. After $0.94 actual earnings per share reported by Canadian National Railway Company for the previous quarter, Wall Street now forecasts -14.89% negative EPS growth.

Among 5 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galmed Pharmaceuticals Ltd had 9 analyst reports since August 14, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of GLMD in report on Tuesday, August 8 with “Buy” rating. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has “Buy” rating given on Monday, March 28 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, August 13 by Roth Capital. Maxim Group maintained the stock with “Buy” rating in Monday, July 31 report. The firm has “Buy” rating by Maxim Group given on Thursday, March 15. The stock has “Hold” rating by Maxim Group on Wednesday, February 14.

Canadian National Railway Company (NYSE:CNI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts